Jecho

Jecho, whose website is published by Jecho Laboratories, Inc. and lists sites in Frederick, Maryland, Shanghai and Tianjin, was founded in 2013, according to the company, and describes three R&D centres, a preclinical animal facility and a pilot and manufacturing base, with a portfolio spanning monoclonal and bispecific antibodies, antibody-drug conjugates, antibody radionuclide conjugates, fusion proteins, immunotoxins and oncolytic viruses. Its Chinese company Jecho Biopharmaceuticals Co., Ltd. sponsors the registry trials: JL15003, given by a single intratumoural injection with viral shedding measured, completed a phase 1 study in recurrent glioblastoma (NCT07497373) and is in a phase 1b/2 trial (NCT07501559); JL19001 is in a phase 1/2 trial alone or with BCG in high-risk non-muscle invasive bladder cancer (NCT07483970) and a phase 1 trial in advanced solid tumours or relapsed B-cell non-Hodgkin lymphoma (NCT07603479); and JLM019, given intravenously, is in a phase 1 trial in advanced solid tumours and lymphoma (NCT07623850). The sponsor also ran a phase 3 comparison of JL14002 with Lucentis in wet age-related macular degeneration (NCT07389577), which was not a cancer study. Its first registered cancer trial, NCT07483970, was posted on ClinicalTrials.gov in March 2026.